Company intelligence / Profile preview

Alivexis, Inc.

Ownership: Private
Development stage: Preclinical

Overview

Multiple novel drug candidates have been discovered and are advancing toward clinical trials, with three lead projects crystallized as clinical development candidates as of March 2024[5].

Therapeutic areas: OncologyRare DiseasesImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

MOD-D

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Alivexis, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alivexis, Inc..

Explore the full profile